CSLLY - CSL Limited said to be in talks to buy Swiss drugmaker Vifor Pharma

Australian biotech company, CSL Limited (OTCPK:CSLLY) (OTCPK:CMXHF), is reportedly in exclusive talks to buy Vifor Pharma (OTCPK:GNHAF) (OTCPK:GNHAY) for A$10 billion ($7.10 billion), The Australian newspaper said on Thursday, according to Reuters. Swiss drugmakers’ shares on the SIX Swiss Exchange have surged in reaction. The negotiations between the two companies have advanced since the newspaper reported in March about a potential buyout deal between CSL and Vifor, a pharmaceutical company headquartered in Sankt Gallen, Switzerland. Both companies have declined comment. Based in Parkville, Australia, CSL Limited (OTCPK:CSLLY) operates two segments: CSL Behring and Seqirus. The company reported $2.3B in net profits for fiscal 2021 with ~13% YoY growth after revenue surged ~10% YoY to $10.3B. For fiscal 2022, the company expects its revenue to grow by ~2 – 5% on a constant currency basis.

For further details see:

CSL Limited said to be in talks to buy Swiss drugmaker Vifor Pharma